Spero Therapeutics, Inc. (SPRO) News

Spero Therapeutics, Inc. (SPRO): $1.47

0.01 (-0.68%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add SPRO to Watchlist
Sign Up

Filter SPRO News Items

SPRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SPRO News From Around the Web

Below are the latest news stories about SPERO THERAPEUTICS INC that investors may wish to consider to help them evaluate SPRO as an investment opportunity.

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript November 13, 2023 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $-0.15. Ted Jenkins: Thank you, operator, and thank you all for participating in today’s conference call. This afternoon, Spero Therapeutics released financial results and provided a pipeline update for the third […]

Yahoo | November 14, 2023

Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update

Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR

Yahoo | November 13, 2023

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide

Yahoo | November 6, 2023

Spero Therapeutics to Present at Upcoming November Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at

Yahoo | November 1, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations.CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of

Yahoo | November 1, 2023

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on October 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 65,000 restricted stock unit awards (RSUs) to

Yahoo | October 31, 2023

All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | October 18, 2023

Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald’s Gl

Yahoo | September 20, 2023

Insider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics Inc

On September 13, 2023, Chief Medical Officer Kamal Hamed sold 39,496 shares of Spero Therapeutics Inc (NASDAQ:SPRO).

Yahoo | September 16, 2023

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. “We are excited to welcome David to our Board,” said Dick Simon, Chief Executive Officer of Sensorium. “He is a seasoned life sciences executive with a track record of success that spans mult

Yahoo | September 12, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!